Elevance Health disclosed a permanent downward revision to its long-term health benefits margin target during its Q4 2025 earnings call on January 28, 2026. Management lowered the target from the prior framework to "mid-single-digit," citing three structural drivers: elevated cost trends, a larger share of ACA business relative to commercial group coverage, and overall business mix shifts. Management emphasized this represents "not a change in strategy or discipline" but rather a recalibration to the current operating environment.

The margin reset accompanies a deliberate strategic exit from unprofitable Medicare Advantage markets. The company expects MA membership to decline by "high teens percentage" in 2026 as it exits underperforming PPO products and concentrates on D-SNP and HMO plans. Management stated this repositioning targets "greater than 100 basis points" of margin improvement in MA, raising the segment to "at least 2%" margin in 2026.

Medicare reimbursement pressure emerged as an industry-wide issue. Management characterized the Advance Notice rates as "effectively flat," stating they "don't keep pace with cost trends." This marks a public pushback on reimbursement adequacy, with risk adjustment framework changes adding further uncertainty.

The strategic pivot comes at a short-term earnings cost. The company guided 2026 EPS to "at least $25.50," down from $30.29 in 2025 (though 2025 included $3.75 in nonrecurring tax benefits). Management reaffirmed its 12% long-term growth algorithm starting in 2027, positioning 2026 as a transition year.

Medicaid was identified as reaching a "trough year" in 2026, with margin guidance of -1.75%. Cost trends remain "mid-single-digit percentage" — double historical levels but moderating — while rate increases lag despite being mid-single-digit themselves.

Cash flow guidance improved materially: the company expects "at least $5.5 billion" in operating cash flow for 2026, up from $4.3 billion in 2025 (which was impacted by Medicaid payment timing). Capital allocation includes $2.3 billion in share buybacks and a conservative M&A posture focused on integration.

This recalibration occurred within 24 hours of UnitedHealth Group's Q4 2025 call, where UNH similarly disclosed MA membership declines (1.3-1.4M members) and prioritized margin over market share. Both transcripts independently described reimbursement rates failing to keep pace with cost trends and multi-year margin framework adjustments, suggesting an industry-level structural shift rather than company-specific execution issues.